7 August 2017 - Maintenance treatment option designed to eliminate the need for hand-breath co-ordination during inhalation.

Teva Pharmaceutical Industries announced today that the U.S. FDA has approved Qvar RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older. Qvar RediHaler is not indicated for the relief of acute bronchospasm. 

The product is expected to become commercially available in both 40  mcg and 80 mcg strengths to patients by prescription during the first quarter of 2018.

Read Teva Pharmaceuticals press release